T Telehealth Options

Medication comparison

Tirzepatide vs semaglutide: which weight-loss medication is better?

Tirzepatide and semaglutide are two of the most discussed injectable medications for medical weight loss. Tirzepatide has shown greater average weight loss in a head-to-head obesity trial, but the right choice depends on medical history, side effects, coverage, and clinician guidance.

Check eligibility factors Compare medications
Home Tirzepatide vs Semaglutide for Weight Loss

Mechanism

Tirzepatide targets GIP and GLP-1 receptors; semaglutide targets GLP-1 receptors.

Learn more

Brand examples

Zepbound is tirzepatide for weight management; Wegovy is semaglutide for weight management.

Learn more

Decision factors

Health history, side effects, contraindications, coverage, supply, and follow-up.

Learn more

Quick comparison

Feature Tirzepatide Semaglutide
Receptor activity GIP and GLP-1 receptor agonist. GLP-1 receptor agonist.
Weight-management brand example Zepbound. Wegovy.
Diabetes brand example Mounjaro. Ozempic.
Typical administration Once-weekly injection with dose escalation. Once-weekly injection for Wegovy and Ozempic; oral semaglutide exists for diabetes under separate labeling.
Average weight loss in SURMOUNT-5 20.2% average body-weight reduction at 72 weeks in adults without diabetes. 13.7% average body-weight reduction at 72 weeks in adults without diabetes.
How it is used With reduced-calorie diet and increased physical activity when prescribed for chronic weight management. With reduced-calorie diet and increased physical activity when prescribed for chronic weight management.
Common side effects Gastrointestinal effects such as nausea, vomiting, diarrhea, constipation, or abdominal discomfort may occur. Gastrointestinal effects such as nausea, vomiting, diarrhea, constipation, or abdominal discomfort may occur.
Cost and access Depends on indication, insurance, prior authorization, pharmacy availability, and telehealth provider policy. Depends on indication, insurance, prior authorization, pharmacy availability, and telehealth provider policy.
Conversation points Dose escalation, gastrointestinal side effects, contraindications, cost, availability, and monitoring. Dose escalation, gastrointestinal side effects, contraindications, cost, availability, and monitoring.

Find out which treatment may fit your situation

Use the eligibility quiz to prepare for a licensed telehealth consultation about tirzepatide, semaglutide, or other medical weight-loss options.

  • Estimate common BMI discussion thresholds.
  • Prepare questions about risks, cost, and medication access.
  • Discuss options with a licensed provider if appropriate.
Check eligibility

What tirzepatide is

Tirzepatide is the active ingredient in Zepbound for chronic weight management and Mounjaro for type 2 diabetes. It activates both GIP and GLP-1 receptors and is prescribed under specific product labeling depending on the diagnosis and clinical context.

What semaglutide is

Semaglutide is the active ingredient in Wegovy for chronic weight management and Ozempic for type 2 diabetes. It activates GLP-1 receptors and is also prescribed under product-specific labeling based on the patient’s diagnosis and treatment goal.

Key differences

The biggest mechanism difference is that tirzepatide acts on both GIP and GLP-1 receptors, while semaglutide acts on GLP-1 receptors. Both medications are commonly discussed in telehealth weight-loss consultations, but they are not interchangeable without clinician guidance.

  • Tirzepatide weight-management brand: Zepbound.
  • Semaglutide weight-management brand: Wegovy.
  • Both require safety screening, dose planning, and follow-up.

Effectiveness comparison

In the SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight loss than semaglutide at 72 weeks in adults with obesity or overweight and at least one weight-related condition, but without diabetes. Trial averages do not predict an individual patient’s result.

Side effects comparison

Both medications can cause gastrointestinal side effects, especially during dose escalation. Patients should ask about nausea, vomiting, diarrhea, constipation, dehydration risk, gallbladder symptoms, severe abdominal pain, allergic reactions, and what symptoms require urgent evaluation.

Cost and access comparison

Cost and access can be just as important as effectiveness. Insurance coverage, prior authorization, diagnosis, supply, manufacturer programs, pharmacy route, and telehealth program fees can all affect whether tirzepatide or semaglutide is realistic for a patient.

How clinicians may think through the choice

The decision is not only about average weight-loss results. Clinicians may consider prior response, diabetes status, cardiovascular history, kidney or gallbladder concerns, pregnancy plans, insurance formulary, supply, and how a patient tolerates dose changes.

What patients should ask

Use the comparison to guide a specific conversation instead of self-selecting a medication.

  • Which FDA-approved option fits my diagnosis and risk profile?
  • What side effects would make us pause, reduce, or stop treatment?
  • What is the plan if insurance denies coverage or supply is interrupted?

Related telehealth guides

Frequently asked questions

Is tirzepatide stronger than semaglutide?

In SURMOUNT-5, tirzepatide led to greater average weight loss than semaglutide. “Stronger” is not the only factor because safety, side effects, medical history, cost, and coverage matter.

Which leads to more weight loss, tirzepatide or semaglutide?

In a 72-week head-to-head obesity trial, tirzepatide produced greater average weight loss than semaglutide. Individual results vary and should be discussed with a clinician.

Are tirzepatide and semaglutide both GLP-1 medications?

Semaglutide is a GLP-1 receptor agonist. Tirzepatide is often discussed alongside GLP-1 medications because it activates GLP-1 receptors, but it also activates GIP receptors.

Can I switch from semaglutide to tirzepatide online?

A telehealth clinician may evaluate a switch, but it should account for timing, dose history, side effects, indications, medication access, and safety screening.

Can tirzepatide or semaglutide be prescribed through telehealth?

A licensed telehealth clinician may prescribe when state rules allow and when the medication is clinically appropriate after reviewing eligibility, risks, and follow-up needs.

What are the common side effects?

Both medications commonly cause gastrointestinal symptoms such as nausea, vomiting, diarrhea, constipation, and abdominal discomfort. Serious or persistent symptoms should be reviewed by a clinician.

Sources reviewed

Summary

Tirzepatide activates GIP and GLP-1 receptors, while semaglutide activates GLP-1 receptors. In SURMOUNT-5, tirzepatide led to greater average weight loss than semaglutide, but treatment choice should be individualized by a licensed clinician.

Medical disclaimer

This content is for education only and is not medical advice. Medication decisions should be made with a licensed clinician who can review your full health history. Seek urgent care for emergency symptoms.